-
Yuanmai Cell Biotechnology Secures Angel Funding for Macrophage Immunotherapy
•
Yuanmai Cell Biotechnology Co., Ltd, a macrophage immunotherapy developer based in Nanjing, reportedly raised “tens of millions” of renminbi in an angel financing round. CDH Investments and Renai Group led the funding, which included contributions from Nanjing Jiangbei New Area Sci-tech Investment Group and Nanjing Laoyan Venture Capital. Proceeds will…
-
Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the clinical trial approval and research and development (R&D) materials of 18F-APN-1607, a Tau protein positron photography tracer used for PET imaging diagnosis, from Japan’s Aprinoia Therapeutics Inc. and Aprinoia Therapeutics Suzhou, along with exclusive clinical…
-
Shanghai Hantong Medtech Raises Angel Funding for Ultrasound Platform
•
Shanghai Hantong Medical Technology Co., Ltd reportedly raised “tens of millions” of renminbi in an angel financing round led by Cowin Capital. Other investors included HiMed Angel Fund and Joyin Center. Proceeds will go towards interventional ultrasound platform construction, product research and development, and manufacturing. Company Focus and TechnologyHantong Medtech,…
-
GenAssist Therapeutics Secures Series A Funding for Gene Therapy Development
•
China’s Suzhou GenAssist Therapeutics Co., Ltd, a base editing technology-based gene therapy developer, reportedly raised “tens of millions” of US dollars in a Series A financing round. The medical business jointly set up by AstraZeneca and CICC Capital led the round, which included contributions from Baidu Venture, Sequoia Capital China,…
-
Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA
•
The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s (HKG: 3692) generic version of Japan firm Takeda Pharmaceutical Co., Ltd’s Firazyr (icatibant) has been approved for marketing in China. Firazyr: Mechanism and Approval HistoryFirazyr, a selective bradykinin B2 receptor antagonist developed by Shire Pharmaceuticals,…
-
NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China
•
The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi Lo (efavirenz, lamivudine, tenofovir) has been approved for marketing in China. The drug was awarded priority review status in May 2020 for use in human immunodeficiency virus type 1 (HIV-1) infection in adults and children…
-
SciClone’s Danyelza Approved for Marketing in China by NMPA
•
The National Medical Products Administration (NMPA) website indicates that SciClone Pharmaceuticals Inc’s (Nasdaq: SCLN) Danyelza (naxitamab) has been approved for marketing in China. Danyelza is a GD2-targeted monoclonal antibody originated by Y-mAbs Therapeutics Inc., and was fast-tracked for marketing approval in November 2020. SciClone struck a licensing deal with Y-mAbs…
-
Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study
•
AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) released the latest data supporting the antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) as a new standard of care for breast cancer. An update from the DESTINY-Breast03 Phase III study assessing Enhertu head-to-head against Roche’s Kadcyla (trastuzumab emtansine, TDM-1) in patients with…
